Segesterone acetate/ethinylestradiol
Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, and, estrogen.[1] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][2]
Combination of | |
---|---|
Segesterone acetate | Progestogen |
Ethinylestradiol | Estrogen |
Clinical data | |
Trade names | Annovera |
Other names | EE/SGA; EE/SA |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a604032 |
License data | |
Routes of administration | Intravaginal |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[3] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.[1]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.[2][4]
See also
References
- "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
- "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control". TherapeuticsMD Inc (Press release). 10 August 2018. Retrieved 10 October 2020.
- "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDS) (Press release). 10 August 2018. Retrieved 10 October 2020.
- "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.
External links
- "Segesterone acetate". Drug Information Portal. U.S. National Library of Medicine.
- "Ethinylestradiol". Drug Information Portal. U.S. National Library of Medicine.
Comparison | |||||
---|---|---|---|---|---|
Behavioral |
| ||||
Barrier and / or spermicidal | |||||
Hormonal (formulations) |
| ||||
Anti-estrogen |
| ||||
Post-intercourse | |||||
Intrauterine device | |||||
Sterilization |
| ||||
Experimental | |||||
Long-acting reversible contraception (LARC) |
Progestogens (and progestins) |
| ||||
---|---|---|---|---|---|
Antiprogestogens |
| ||||
|
ER |
| ||||||
---|---|---|---|---|---|---|---|
GPER |
| ||||||
|
PR |
| ||||||
---|---|---|---|---|---|---|---|
mPR (PAQR) |
| ||||||
|